Latest Shareholder Value News

Codrus Minerals reports encouraging initial diamond drilling results at its Bull Run Gold Project in Oregon, while progressing uranium exploration in Canada and executing a significant asset sale in Western Australia.

Dateline Resources has bolstered its financial position with a $35 million institutional placement, setting the stage for expanded drilling and a strategic transition to U.S. reporting standards at its Colosseum Gold-REE Project in California.

Cyprium Metals has raised A$41 million through an oversubscribed equity placement and entitlement offer to accelerate exploration and production growth at its flagship Nifty Copper Complex and regional projects.

Global Uranium and Enrichment Limited has finalised the share and option scheme considerations for its acquisition by Snow Lake Resources, with directors backing the deal ahead of the upcoming shareholder vote.

Visionflex Group’s Q2 FY26 report reveals a 23% rise in annual recurring revenue and improved cash flow, even as overall revenue slips due to lower hardware sales.

Bounty Oil & Gas has announced a significant board renewal, including the appointment of Kane Marshall as Chairman and the retirement of long-serving CEO Philip Kelso. These leadership changes mark a new chapter as the company pursues growth in its Australian oil and gas assets.

Clover Corporation has initiated an on-market acquisition of up to 3.26 million shares to satisfy future employee share plan vesting, aiming to reduce shareholder dilution from new share issuances.

Coventry Group reports a solid half-year sales and earnings improvement while initiating a strategic review following unsolicited takeover interest.

SSH Group Ltd reports a robust half-year performance with revenue up 25%, operational advances in gold projects, and a new strategic partnership enhancing its mining capabilities.

Xenora Minerals has resumed on-ground exploration at its Dudley Lithium Project in South Australia following a detailed geochemical review, supported by a recent $2.1 million capital raise. The company ends the quarter with a strong cash position, positioning itself for further growth in the critical minerals sector.

Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.

AMCIL Limited has announced a fresh on-market buy-back program targeting up to 24 million shares, aiming to enhance capital management without requiring shareholder approval.